Romidepsin (INN trade name Istodax) codenamed FK228 and FR901228 is an anticancer agent undergoing clinical trials as a treatment for cutaneous T-cell lymphoma (CTCL) peripheral T-cell lymphoma and a variety of other cancers. Romidepsin is a natural product obtained from the bacteria Chromobacterium violaceum and works by blocking enzymes known as histone deacetylases and inducing apoptosis.
This page contains content from the copyrighted Wikipedia article "Romidepsin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
.svg?width=300)